Advertisement
Home »

Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors.

Jul 25, 2023

ABOUT THE EXPERTS

  • Cristina Suárez

    Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain.

    Maria Vieito

    Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain.

    Augusto Valdivia

    Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain.

    Macarena González

    Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain.

    Joan Carles

    Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Hospital Universitari Vall d’Hebron, 08035 Barcelona, Spain.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement